2393 Stock Overview
Yestar Healthcare Holdings Company Limited, an investment holding company, engages in the manufacture, distribution, and sale of medical imaging products in Mainland China.
Yestar Healthcare Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$0.66|
|52 Week High||HK$1.29|
|52 Week Low||HK$0.60|
|1 Month Change||-22.35%|
|3 Month Change||-26.67%|
|1 Year Change||-41.07%|
|3 Year Change||-53.52%|
|5 Year Change||-81.87%|
|Change since IPO||67.09%|
Recent News & Updates
|2393||HK Medical Equipment||HK Market|
Return vs Industry: 2393 exceeded the Hong Kong Medical Equipment industry which returned -54.1% over the past year.
Return vs Market: 2393 underperformed the Hong Kong Market which returned -22.7% over the past year.
|2393 Average Weekly Movement||8.7%|
|Medical Equipment Industry Average Movement||8.7%|
|Market Average Movement||6.6%|
|10% most volatile stocks in HK Market||12.8%|
|10% least volatile stocks in HK Market||3.2%|
Stable Share Price: 2393 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: 2393's weekly volatility (9%) has been stable over the past year.
About the Company
Yestar Healthcare Holdings Company Limited, an investment holding company, engages in the manufacture, distribution, and sale of medical imaging products in Mainland China. It operates through two segments, Imaging Printing Products, and Medical Products and Equipment. The Imaging Printing Products segment manufactures and sells Fujifilm color photographic paper, industrial NDT X-ray films, and PWB films; and trades in imaging equipment.
Yestar Healthcare Holdings Fundamentals Summary
|2393 fundamental statistics|
Is 2393 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|2393 income statement (TTM)|
|Cost of Revenue||CN¥4.08b|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||0.0014|
|Net Profit Margin||0.067%|
How did 2393 perform over the long term?See historical performance and comparison
Is 2393 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2393?
Other financial metrics that can be useful for relative valuation.
|What is 2393's n/a Ratio?|
Price to Sales Ratio vs Peers
How does 2393's PS Ratio compare to its peers?
|2393 PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
2276 Shanghai Conant Optical
1501 Shanghai Kindly Medical Instruments
2170 Suzhou Basecare Medical
1763 China Isotope & Radiation
2393 Yestar Healthcare Holdings
Price-To-Sales vs Peers: 2393 is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (4.9x).
Price to Earnings Ratio vs Industry
How does 2393's PE Ratio compare vs other companies in the HK Medical Equipment Industry?
Price-To-Sales vs Industry: 2393 is good value based on its Price-To-Sales Ratio (0.3x) compared to the Hong Kong Medical Equipment industry average (5.8x)
Price to Sales Ratio vs Fair Ratio
What is 2393's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||0.3x|
|Fair PS Ratio||0.7x|
Price-To-Sales vs Fair Ratio: 2393 is good value based on its Price-To-Sales Ratio (0.3x) compared to the estimated Fair Price-To-Sales Ratio (0.7x).
Share Price vs Fair Value
What is the Fair Price of 2393 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 2393 (HK$0.66) is trading below our estimate of fair value (HK$5)
Significantly Below Fair Value: 2393 is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Yestar Healthcare Holdings forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 2393's forecast earnings growth is above the savings rate (1.6%).
Earnings vs Market: Insufficient data to determine if 2393's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 2393's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 2393's revenue (7.5% per year) is forecast to grow slower than the Hong Kong market (10% per year).
High Growth Revenue: 2393's revenue (7.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2393's Return on Equity is forecast to be very high in 3 years time (58%).
Discover growth companies
How has Yestar Healthcare Holdings performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2393 has high quality earnings.
Growing Profit Margin: 2393 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: 2393's earnings have declined by 40.8% per year over the past 5 years.
Accelerating Growth: 2393 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 2393 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (35.4%).
Return on Equity
High ROE: 2393's Return on Equity (1.5%) is considered low.
Discover strong past performing companies
How is Yestar Healthcare Holdings's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 2393's short term assets (CN¥2.8B) exceed its short term liabilities (CN¥2.2B).
Long Term Liabilities: 2393's short term assets (CN¥2.8B) exceed its long term liabilities (CN¥1.6B).
Debt to Equity History and Analysis
Debt Level: 2393's net debt to equity ratio (99.2%) is considered high.
Reducing Debt: 2393's debt to equity ratio has increased from 177.5% to 189.5% over the past 5 years.
Debt Coverage: 2393's debt is well covered by operating cash flow (45.4%).
Interest Coverage: 2393's interest payments on its debt are not well covered by EBIT (1.5x coverage).
Discover healthy companies
What is Yestar Healthcare Holdings's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 2393's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 2393's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2393's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2393's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: 2393 is not paying a notable dividend for the Hong Kong market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 2393 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
James Hartono (46 yo)
Mr. James Hartono serves as Executive Chairman of The Board and Chief Executive Officer of Yestar Healthcare Holdings Company Limited (formerly known as Yestar International Holdings Company Limited). Mr....
CEO Compensation Analysis
Compensation vs Market: James's total compensation ($USD570.59K) is above average for companies of similar size in the Hong Kong market ($USD303.06K).
Compensation vs Earnings: James's compensation has been consistent with company performance over the past year.
Experienced Management: 2393's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Experienced Board: 2393's board of directors are considered experienced (8.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Yestar Healthcare Holdings Company Limited's employee growth, exchange listings and data sources
- Name: Yestar Healthcare Holdings Company Limited
- Ticker: 2393
- Exchange: SEHK
- Founded: 1971
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: HK$1.679b
- Shares outstanding: 2.33b
- Website: https://www.yestarcorp.com
Number of Employees
- Yestar Healthcare Holdings Company Limited
- Green Land Building
- Floor 8, Block A
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/10 00:00|
|End of Day Share Price||2022/08/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.